Tokyo, June 16, 2006 (JCN) - Dainippon Sumitomo Pharma will release AmBisome 50mg for intravenous drip infusion, an antifungal agent for treating deep-seated mycosis infection, on June 20.
AmBiosome, which the company has licensed from US company Gilead Sciences, is a liposomal formulation of amphotericin B. It retains the efficacy of amphotericin B while reducing the damage to kidneys.
AmBisome is the only antifungal agent indicated for the treatment of febrile neutropenia with suspected mycotic infection. The agent is currently available in 45 countries worldwide.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore
(Jan 22, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent
(Dec 28, 2012)
|
|
|
NOTICE of establishment of Drug Discovery Consortium in neuropsychiatric area
(Oct 23, 2008)
|
|
|
Dainippon Sumitomo, AstraZeneca to Develop Antiallergic Drug
(May 8, 2008)
|
|
|
Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic
(Dec 13, 2006)
|
|
|
Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent
(Nov 28, 2006)
|
|
|
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'
(Sept 21, 2006)
|
|
|
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'
(Sept 21, 2006)
|
|
|
Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs
(July 26, 2006)
|
|
|
Dainippon Sumitomo Pharma to Release AmBisome 50mg, Antifungal Agent for Deep-seated Mycosis Infection
(June 16, 2006)
|
|
|
